Bryn Mawr Capital Management LLC Has $4.17 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Bryn Mawr Capital Management LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 61,866 shares of the company’s stock after purchasing an additional 164 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in AstraZeneca were worth $4,167,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of AZN. Wellington Management Group LLP boosted its stake in AstraZeneca by 0.7% in the third quarter. Wellington Management Group LLP now owns 49,492,814 shares of the company’s stock valued at $3,351,653,000 after buying an additional 358,399 shares in the last quarter. Jennison Associates LLC boosted its stake in AstraZeneca by 5.2% in the third quarter. Jennison Associates LLC now owns 22,946,504 shares of the company’s stock valued at $1,553,937,000 after buying an additional 1,139,295 shares in the last quarter. Sanders Capital LLC acquired a new stake in AstraZeneca in the third quarter valued at about $715,198,000. Ameriprise Financial Inc. boosted its stake in AstraZeneca by 5.0% in the third quarter. Ameriprise Financial Inc. now owns 4,242,708 shares of the company’s stock valued at $287,294,000 after buying an additional 201,104 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in AstraZeneca by 1.5% in the third quarter. Northern Trust Corp now owns 3,274,928 shares of the company’s stock valued at $221,778,000 after buying an additional 48,524 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AZN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Morgan Stanley began coverage on AstraZeneca in a research note on Tuesday, January 23rd. They set an “overweight” rating on the stock. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, BMO Capital Markets lifted their price target on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $81.00.

AstraZeneca Trading Up 0.2 %

Shares of AZN traded up $0.14 during mid-day trading on Friday, reaching $75.17. 6,687,806 shares of the company were exchanged, compared to its average volume of 6,265,456. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $75.81. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.64 and a current ratio of 0.82. The stock has a market capitalization of $233.06 billion, a PE ratio of 39.15, a PEG ratio of 1.31 and a beta of 0.50. The business has a 50 day simple moving average of $67.27 and a two-hundred day simple moving average of $66.07.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The company had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. AstraZeneca’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.69 earnings per share. On average, analysts predict that AstraZeneca PLC will post 4 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently announced a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were issued a $0.965 dividend. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a yield of 2.3%. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s payout ratio is presently 100.52%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.